Abstract 849P
Background
Many disease processes are thought to be impacted by altered long non-coding RNAs (lncRNAs) expression. lncRNAs are typically expressed differently throughout healthy and cancerous hematopoiesis. In the domains of haematology and oncology, they represent a class of biomarkers that is receiving increasing attention. According to recent studies, the expression levels of particular lncRNAs are correlated with the prognosis of paediatric patients with acute lymphoblastic leukaemia. To determine the potential roles of lncRNAs involved in pathogenesis of T-ALL, we analyzed the expression profile of lncRNAs in pediatric T-ALL.
Methods
Twenty five pediatric T-All patients were enrolled and subjected to whole transcriptome analysis in comparison with healthy controls. The results from NGS were validated ex vivo, using real time PCR in the same cases and in a different cohort of 25 T-ALL cases and healthy controls. The results were also comapred with public databases in silico. Potential functions of subtype-specific lncRNAs were determined by using coexpression-based analysis on distally (trans-pattern) located protein-coding genes.
Results
A total of 672 differentially expressed lncRNAs were identified. Moreover, the top 10 upregulated lncRNAs were selected and further assessed by RT-qPCR in vitro in the same samples and a different cohort. We found that lncRNAs LINC01221, LINC00977, RP11-472G21.2 and CTD-2291D10.4 were highly over expressed (>10 fold) in the patients while PCAT18, CRNDE, and RP11-620J15.3 showed mild overexpression (2 to 5 fold increase). The expression of these lncRNAs were also increased in Peer and CCRF-CEM cell lines. Finally, expression correlation analyses using weighted gene co-relation analysis of T-ALL selected lncRNAs and mRNAs suggested that lncRNAs LINC01221, LINC00977, CTD-2291D10.4 may play a possible role in lymphocyte activation and cell.
Conclusions
These results showed that several lncRNAs are aberrantly expressed in T-ALL patients and play potential roles in T-ALL development, and can be useful for diagnostic and/or prognostic purposes in pediatric T-ALL. This study provides the keystone to future clinical studies determining the theragnostic value of the characterized long non-coding transcriptome panorama in a clinical setting for childhood patient management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Post Graduate Institute of Medical Education and Research.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
978P - Post-progression outcomes of advanced HCC patients (aHCC pts) treated with first-line atezolizumab/bevacizumab (A/B)
Presenter: Claudia Fulgenzi
Session: Poster session 18
979P - Safety interim analyses of first-line systemic therapy with atezolizumab plus bevacizumab (ATZ+BEV) in patients from Spain with unresectable hepatocellular carcinoma (HCC): Phase IIIb ATHECA
Presenter: Maria Elisa Reig Monzon
Session: Poster session 18
980P - Neutrophil count predicts the complete response after transarterial chemoembolization related to favorable outcome in hepatocellular carcinoma
Presenter: Young Mi Hong
Session: Poster session 18
981P - The response of portal vein tumoral thrombosis to moderately hypo-fractionated radiotherapy using intensity modulated radiotherapy
Presenter: Ahmad Abdel-Azeez
Session: Poster session 18
982P - Transarterial chemoembolization with idarubicin versus epirubicin for hepatocellular carcinoma: An interim analysis of a multicentre, randomized controlled phase III trial
Presenter: Zhewei Zhang
Session: Poster session 18
983P - Safety and efficacy of durvalumab plus hepatic artery infusion chemotherapy in HCC with severe portal vein tumor thrombosis (Vp3/4) – the DurHope study
Presenter: Ming Zhao
Session: Poster session 18
984P - Comparative study of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma: A nationwide cohort study
Presenter: Jo Kook Lee
Session: Poster session 18
987P - Safety and efficacy of lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Korea
Presenter: Wonseok Kang
Session: Poster session 18
988P - Burden of primary liver cancer in the Middle East and North Africa Region from 1990 to 2019
Presenter: Ahmed Hafez Allam
Session: Poster session 18